David Reardon, MD

Articles by David Reardon, MD

Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM

ByDavid Reardon, MD

November 18th 2016

Dr. Reardon on Updated Data From the Phase II ReACT Trial

ByDavid Reardon, MD

November 20th 2015

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.

Dr. Reardon Discusses Rindopepimut Plus Bevacizumab in Glioblastoma

ByDavid Reardon, MD

November 15th 2014

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, discusses the ReACT study, which examined the rindopepimut vaccine (CDX-110) plus bevacizumab in patients with relapsed glioblastoma.